Exelixis Inc (EXEL) 1.74 $EXEL
Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma
Business Wire - Thu Nov 06, 5:01AM CST
-- Primary Analysis of PFS Endpoint to Be Conducted on First 375 Patients Enrolled --
EXEL: 1.74 (+0.07)
Hot Stock: Exelixis, Shares Gain 10.9% (EXEL)
Comtex SmarTrend(R) - Wed Nov 05, 11:38AM CST
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 10.9% to $1.83 on 1.1x average daily volume. Thus far today, Exelixis has traded 3.3 million shares, vs. average volume of 3.1 million shares per day. The stock has outperformed the Dow (10.9% to the Dow's 0.5%) and outperformed the S&P 500 (10.9% to the S&P's 0.4%) during today's trading.
EXEL: 1.74 (+0.07)
Exelixis' Cometriq Makes a Comeback
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 04, 7:40PM CST
Exelixis rose 10% in after-hours trading Tuesday after releasing third-quarter earnings, but the increase had nothing to do with the revenue it generated. Sales of its only approved drug, Cometriq, came it at just $6.3 million in the third...
NVS: 91.76 (-0.27), EXEL: 1.74 (+0.07)
Exelixis tops 3Q profit forecasts
Automated Insights - Tue Nov 04, 6:21PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Exelixis Inc. (EXEL) on Tuesday reported a loss of $62.6 million in its third quarter.
EXEL: 1.74 (+0.07)
Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
Business Wire - Tue Nov 04, 3:14PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis. Study E1512 was designed and is being conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis' collaboration with the NCI. Joel Neal, M.D., Ph.D., from ECOG-ACRIN member institution Stanford University/Stanford Cancer Institute, chairs the study.
EXEL: 1.74 (+0.07)
Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Tue Nov 04, 3:13PM CST
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the third quarter of 2014 and provided an update on its progress toward delivering upon its key corporate objectives and clinical development milestones.
EXEL: 1.74 (+0.07)
Why Exelixis, Inc. Stock Pushed 11% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 04, 1:04PM CST
EXEL data by YCharts What: Shares of Exelixis , a biopharmaceutical company focused on developing therapies targeted at cancer, rallied 11% in October, based on data from S&P Capital IQ , as investors' nerves calmed down from the month...
EXEL: 1.74 (+0.07)
Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:35PM CST
Exelixis, Inc. (EXEL) is slated to report its third-quarter 2014 results on Nov 4.
ACT: 245.91 (-4.47), HSP: 56.32 (-0.32), EXEL: 1.74 (+0.07)
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 83.91 (-0.12), LXRX: 1.35 (-0.13), AMGN: 160.25 (-0.10), REGN: 377.84 (+0.90), EXEL: 1.74 (+0.07)
Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014
Business Wire - Tue Oct 14, 3:12PM CDT
Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2014 financial results will be released on Tuesday, November 4, 2014 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the Company's financial results for the third quarter 2014 and provide a general business update. The conference call will be accessible via the Internet from the Company's website.
EXEL: 1.74 (+0.07)
Is Exelixis, Inc. Stock a Bad News Buy?
Motley Fool Staff - Motley Fool - Mon Oct 13, 7:30AM CDT
Clinical or regulatory setbacks can cause biotechnology stocks to crash in a hurry. On occasion, the market's pessimism isn't entirely warranted, setting the stock up for an equally impressive comeback. Deciphering which "bad news biotechs" are...
BMY: 58.32 (-0.14), EXEL: 1.74 (+0.07)
3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 3.85 (-0.05), VVUS: 3.33 (-0.08), NPSP: 27.49 (+0.15), ARNA: 4.26 (+0.01), EXEL: 1.74 (+0.07)
Roche Presents Data on Cancer Immunotherapy Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 8:50AM CDT
Roche recently announced encouraging preliminary combination data from a phase Ib study on cancer immunotherapy candidate MPDL3280A (anti-PDL1) in combination with Avastin.
JNJ: 108.20 (-0.81), BMY: 58.32 (-0.14), EXEL: 1.74 (+0.07)
Exelixis (EXEL) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 8:41AM CDT
Exelixis (EXEL) Is in Oversold Territory: What’s Next?
EXEL: 1.74 (+0.07)
Thyroid Cancer Market Analysis - API Manufacturers and Phase III Pipeline Assessment 2014-2015
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sgp9d/thyroid_cancer) has announced the addition of the "Thyroid Cancer Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Thyroid Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Exelixis, Inc. - Pfizer Inc. - Genzyme Corporation - Bracco Diagnostics Inc. - Mallinckrodt plc - Sandoz Inc. - Forest Laboratories, Inc. - Institut Biochimique SA - Jubilant DraxImage Inc. For more information visit http://www.researchandmarkets.com/research/5s...oid_cancer
PFE: 29.92 (-0.12), FRX: 99.00 (-0.77), EXEL: 1.74 (+0.07)
Big News for These 5 Stocks From ESMO
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 30, 8:05AM CDT
The news from the European Society for Medical Oncology meeting, or ESMO, came mostly from the large pharmas -- Roche , Merck , and AstraZeneca in particular -- but a couple of smaller biotechs are benefiting. Shares of Clovis Oncology and ...
CLVS: 58.31 (-0.26), MRK: 59.34 (+0.08), AZN: 72.88 (+0.03), BMY: 58.32 (-0.14), EXEL: 1.74 (+0.07)
Market Maker Surveillance Report. EXEL, INTC, KMI, MSFT, ACI, XRX, Bullishly Biased Price Friction For Monday, September 29th 2014
M2 - Tue Sep 30, 3:58AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5089 companies with "abnormal" market making, 1819 companies with positive Friction Factors and 3032 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Exelixis Inc (NASDAQ:EXEL), INTEL CORPORATION (NASDAQ:INTC), KINDER MORGAN INCORPORATED (NYSE:KMI), MICROSOFT CORPORATION (NASDAQ:MSFT), Arch Coal Inc (NYSE:ACI), Xerox Corp (NYSE:XRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
KMI: 38.75 (+0.22), ACI: 2.86 (+0.44), XRX: 13.45 (+0.15), MSFT: 48.68 (-0.02), INTC: 33.58 (-0.24), EXEL: 1.74 (+0.07)
Exelixis Up 7.7%, Shares Break Through Resistance (EXEL)
Comtex SmarTrend(R) - Mon Sep 29, 10:09AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 7.7% to $1.68 on 1.1x average daily volume. Thus far today, Exelixis has traded 5.7 million shares, vs. average volume of 5.2 million shares per day. The stock has outperformed the Dow (7.7% to the Dow's -0.5%) and outperformed the S&P 500 (7.7% to the S&P's -0.4%) during today's trading.
EXEL: 1.74 (+0.07)
Why Exelixis, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Mon Sep 29, 9:38AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of small-cap biopharma Exelixis spiked by...
EXEL: 1.74 (+0.07)
Ahead of the Bell: Exelixis shares soar
AP - Mon Sep 29, 8:19AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) — Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study.
EXEL: 1.74 (+0.07)
Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma
Business Wire - Thu Nov 06, 5:01AM CST
-- Primary Analysis of PFS Endpoint to Be Conducted on First 375 Patients Enrolled --
EXEL: 1.74 (+0.07)
Hot Stock: Exelixis, Shares Gain 10.9% (EXEL)
Comtex SmarTrend(R) - Wed Nov 05, 11:38AM CST
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 10.9% to $1.83 on 1.1x average daily volume. Thus far today, Exelixis has traded 3.3 million shares, vs. average volume of 3.1 million shares per day. The stock has outperformed the Dow (10.9% to the Dow's 0.5%) and outperformed the S&P 500 (10.9% to the S&P's 0.4%) during today's trading.
EXEL: 1.74 (+0.07)
Exelixis' Cometriq Makes a Comeback
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 04, 7:40PM CST
Exelixis rose 10% in after-hours trading Tuesday after releasing third-quarter earnings, but the increase had nothing to do with the revenue it generated. Sales of its only approved drug, Cometriq, came it at just $6.3 million in the third...
NVS: 91.76 (-0.27), EXEL: 1.74 (+0.07)
Exelixis tops 3Q profit forecasts
Automated Insights - Tue Nov 04, 6:21PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Exelixis Inc. (EXEL) on Tuesday reported a loss of $62.6 million in its third quarter.
EXEL: 1.74 (+0.07)
Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
Business Wire - Tue Nov 04, 3:14PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis. Study E1512 was designed and is being conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis' collaboration with the NCI. Joel Neal, M.D., Ph.D., from ECOG-ACRIN member institution Stanford University/Stanford Cancer Institute, chairs the study.
EXEL: 1.74 (+0.07)
Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Tue Nov 04, 3:13PM CST
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the third quarter of 2014 and provided an update on its progress toward delivering upon its key corporate objectives and clinical development milestones.
EXEL: 1.74 (+0.07)
Why Exelixis, Inc. Stock Pushed 11% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 04, 1:04PM CST
EXEL data by YCharts What: Shares of Exelixis , a biopharmaceutical company focused on developing therapies targeted at cancer, rallied 11% in October, based on data from S&P Capital IQ , as investors' nerves calmed down from the month...
EXEL: 1.74 (+0.07)
Will Exelixis (EXEL) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:35PM CST
Exelixis, Inc. (EXEL) is slated to report its third-quarter 2014 results on Nov 4.
ACT: 245.91 (-4.47), HSP: 56.32 (-0.32), EXEL: 1.74 (+0.07)
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 83.91 (-0.12), LXRX: 1.35 (-0.13), AMGN: 160.25 (-0.10), REGN: 377.84 (+0.90), EXEL: 1.74 (+0.07)
Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014
Business Wire - Tue Oct 14, 3:12PM CDT
Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2014 financial results will be released on Tuesday, November 4, 2014 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call to discuss the Company's financial results for the third quarter 2014 and provide a general business update. The conference call will be accessible via the Internet from the Company's website.
EXEL: 1.74 (+0.07)
Is Exelixis, Inc. Stock a Bad News Buy?
Motley Fool Staff - Motley Fool - Mon Oct 13, 7:30AM CDT
Clinical or regulatory setbacks can cause biotechnology stocks to crash in a hurry. On occasion, the market's pessimism isn't entirely warranted, setting the stock up for an equally impressive comeback. Deciphering which "bad news biotechs" are...
BMY: 58.32 (-0.14), EXEL: 1.74 (+0.07)
3 Biotech Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Wed Oct 08, 7:35AM CDT
Source: Pixabay. While the broad-based SPDR S&P Biotech ETF has galloped higher by 20% year-to-date, a number of biotech stocks are wallowing near their 52-week lows. Could there be bargains to be had among this sea of red? With that in...
OREX: 3.85 (-0.05), VVUS: 3.33 (-0.08), NPSP: 27.49 (+0.15), ARNA: 4.26 (+0.01), EXEL: 1.74 (+0.07)
Roche Presents Data on Cancer Immunotherapy Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 8:50AM CDT
Roche recently announced encouraging preliminary combination data from a phase Ib study on cancer immunotherapy candidate MPDL3280A (anti-PDL1) in combination with Avastin.
JNJ: 108.20 (-0.81), BMY: 58.32 (-0.14), EXEL: 1.74 (+0.07)
Exelixis (EXEL) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 8:41AM CDT
Exelixis (EXEL) Is in Oversold Territory: What’s Next?
EXEL: 1.74 (+0.07)
Thyroid Cancer Market Analysis - API Manufacturers and Phase III Pipeline Assessment 2014-2015
M2 - Thu Oct 02, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sgp9d/thyroid_cancer) has announced the addition of the "Thyroid Cancer Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Thyroid Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Exelixis, Inc. - Pfizer Inc. - Genzyme Corporation - Bracco Diagnostics Inc. - Mallinckrodt plc - Sandoz Inc. - Forest Laboratories, Inc. - Institut Biochimique SA - Jubilant DraxImage Inc. For more information visit http://www.researchandmarkets.com/research/5s...oid_cancer
PFE: 29.92 (-0.12), FRX: 99.00 (-0.77), EXEL: 1.74 (+0.07)
Big News for These 5 Stocks From ESMO
Brian Orelli, The Motley Fool - Motley Fool - Tue Sep 30, 8:05AM CDT
The news from the European Society for Medical Oncology meeting, or ESMO, came mostly from the large pharmas -- Roche , Merck , and AstraZeneca in particular -- but a couple of smaller biotechs are benefiting. Shares of Clovis Oncology and ...
CLVS: 58.31 (-0.26), MRK: 59.34 (+0.08), AZN: 72.88 (+0.03), BMY: 58.32 (-0.14), EXEL: 1.74 (+0.07)
Market Maker Surveillance Report. EXEL, INTC, KMI, MSFT, ACI, XRX, Bullishly Biased Price Friction For Monday, September 29th 2014
M2 - Tue Sep 30, 3:58AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5089 companies with "abnormal" market making, 1819 companies with positive Friction Factors and 3032 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Exelixis Inc (NASDAQ:EXEL), INTEL CORPORATION (NASDAQ:INTC), KINDER MORGAN INCORPORATED (NYSE:KMI), MICROSOFT CORPORATION (NASDAQ:MSFT), Arch Coal Inc (NYSE:ACI), Xerox Corp (NYSE:XRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
KMI: 38.75 (+0.22), ACI: 2.86 (+0.44), XRX: 13.45 (+0.15), MSFT: 48.68 (-0.02), INTC: 33.58 (-0.24), EXEL: 1.74 (+0.07)
Exelixis Up 7.7%, Shares Break Through Resistance (EXEL)
Comtex SmarTrend(R) - Mon Sep 29, 10:09AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 7.7% to $1.68 on 1.1x average daily volume. Thus far today, Exelixis has traded 5.7 million shares, vs. average volume of 5.2 million shares per day. The stock has outperformed the Dow (7.7% to the Dow's -0.5%) and outperformed the S&P 500 (7.7% to the S&P's -0.4%) during today's trading.
EXEL: 1.74 (+0.07)
Why Exelixis, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Mon Sep 29, 9:38AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of small-cap biopharma Exelixis spiked by...
EXEL: 1.74 (+0.07)
Ahead of the Bell: Exelixis shares soar
AP - Mon Sep 29, 8:19AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) — Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study.
EXEL: 1.74 (+0.07)
